These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 31556537)

  • 1. Naloxone nasal spray - bioavailability and absorption pattern in a phase 1 study.
    Tylleskar I; Skulberg AK; Nilsen T; Skarra S; Dale O
    Tidsskr Nor Laegeforen; 2019 Sep; 139(13):. PubMed ID: 31556537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of concentrated naloxone nasal spray over first 30 minutes post-dosing: analysis of suitability for opioid overdose reversal.
    Mundin G; McDonald R; Smith K; Harris S; Strang J
    Addiction; 2017 Sep; 112(9):1647-1652. PubMed ID: 28430384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study.
    McDonald R; Lorch U; Woodward J; Bosse B; Dooner H; Mundin G; Smith K; Strang J
    Addiction; 2018 Mar; 113(3):484-493. PubMed ID: 29143400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of a novel, approved, 1.4-mg intranasal naloxone formulation for reversal of opioid overdose-a randomized controlled trial.
    Skulberg AK; Åsberg A; Khiabani HZ; Røstad H; Tylleskar I; Dale O
    Addiction; 2019 May; 114(5):859-867. PubMed ID: 30644628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of a new, nasal formulation of naloxone.
    Tylleskar I; Skulberg AK; Nilsen T; Skarra S; Jansook P; Dale O
    Eur J Clin Pharmacol; 2017 May; 73(5):555-562. PubMed ID: 28144724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics after a single dose of naloxone administered as a nasal spray in healthy volunteers.
    Vanky E; Hellmundt L; Bondesson U; Eksborg S; Lundeberg S
    Acta Anaesthesiol Scand; 2017 Jul; 61(6):636-640. PubMed ID: 28444856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of naloxone nasal spray 4 mg in the community setting: a survey of use by community organizations.
    Avetian GK; Fiuty P; Mazzella S; Koppa D; Heye V; Hebbar P
    Curr Med Res Opin; 2018 Apr; 34(4):573-576. PubMed ID: 28535115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel Faster-Acting, Dry Powder-Based, Naloxone Intranasal Formulation for Opioid Overdose.
    Lapidot T; Bouhajib M; Faulknor J; Khan S; Krayz GT; Abrutzky C; Megiddo D
    Pharm Res; 2022 May; 39(5):963-975. PubMed ID: 35386013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. International patent applications for non-injectable naloxone for opioid overdose reversal: Exploratory search and retrieve analysis of the PatentScope database.
    McDonald R; Danielsson Glende Ø; Dale O; Strang J
    Drug Alcohol Rev; 2018 Feb; 37(2):205-215. PubMed ID: 28597483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world study of multiple naloxone administration for opioid overdose reversal among bystanders.
    Abdelal R; Raja Banerjee A; Carlberg-Racich S; Darwaza N; Ito D; Shoaff J; Epstein J
    Harm Reduct J; 2022 May; 19(1):49. PubMed ID: 35596213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic Properties and Human Use Characteristics of an FDA-Approved Intranasal Naloxone Product for the Treatment of Opioid Overdose.
    Krieter P; Chiang N; Gyaw S; Skolnick P; Crystal R; Keegan F; Aker J; Beck M; Harris J
    J Clin Pharmacol; 2016 Oct; 56(10):1243-53. PubMed ID: 27145977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioavailability investigation of a new tilidine/naloxone liquid formulation compared to a reference formulation.
    Martin W; Ring J; Gaupp M; Arnold P; Sennewald R; Doser K
    Arzneimittelforschung; 1999 Jul; 49(7):599-607. PubMed ID: 10442208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naloxone (Narcan) nasal spray for opioid overdose.
    Med Lett Drugs Ther; 2016 Jan; 58(1485):1-2. PubMed ID: 26714239
    [No Abstract]   [Full Text] [Related]  

  • 14. Naloxone nasal spray.
    Drug Ther Bull; 2019 Sep; 57(9):137-140. PubMed ID: 31296655
    [No Abstract]   [Full Text] [Related]  

  • 15. Intravenous use of intranasal naloxone: A case of overdose reversal.
    Das S; Shah N; Ghadiali M
    Subst Abus; 2017; 38(1):18-21. PubMed ID: 27925864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative pharmacokinetics of nalbuphine nasal spray and solution for injection in healthy volunteers.
    Tymko VG; Tsapko GV; Kovalova KV; Mashchenko SV; Oliinykov DS; Kuznetsov IE
    Br J Clin Pharmacol; 2023 Nov; 89(11):3311-3323. PubMed ID: 37328144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase I, Open-label, Randomized, 2-Way Crossover Study to Evaluate the Relative Bioavailability of Intranasal and Oral Varenicline.
    Nau J; Wyatt DJ; Rollema H; Crean CS
    Clin Ther; 2021 Sep; 43(9):1595-1607. PubMed ID: 34456060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An increase in per-patient naloxone requirements in an opioid epidemic.
    Birmingham LE; Nielson JA
    Am J Emerg Med; 2017 Dec; 35(12):1958-1959. PubMed ID: 28633907
    [No Abstract]   [Full Text] [Related]  

  • 19. A randomized usability assessment of simulated naloxone administration by community members.
    Eggleston W; Podolak C; Sullivan RW; Pacelli L; Keenan M; Wojcik S
    Addiction; 2018 Dec; 113(12):2300-2304. PubMed ID: 30107641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid systemic uptake of naloxone after intranasal administration in children.
    Malmros Olsson E; Lönnqvist PA; Stiller CO; Eksborg S; Lundeberg S
    Paediatr Anaesth; 2021 Jun; 31(6):631-636. PubMed ID: 33687794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.